Your browser doesn't support javascript.
Evidence of Maternal Antibodies Elicited by COVID-19 Vaccination in Amniotic Fluid: Report of Two Cases in Italy.
Colavita, Francesca; Oliva, Alessandra; Bettini, Aurora; Antinori, Andrea; Girardi, Enrico; Castilletti, Concetta; Vaia, Francesco; Liuzzi, Giuseppina.
  • Colavita F; National Institute for Infectious Diseases "L. Spallanzani" IRCCS, 00149 Rome, Italy.
  • Oliva A; National Institute for Infectious Diseases "L. Spallanzani" IRCCS, 00149 Rome, Italy.
  • Bettini A; National Institute for Infectious Diseases "L. Spallanzani" IRCCS, 00149 Rome, Italy.
  • Antinori A; National Institute for Infectious Diseases "L. Spallanzani" IRCCS, 00149 Rome, Italy.
  • Girardi E; National Institute for Infectious Diseases "L. Spallanzani" IRCCS, 00149 Rome, Italy.
  • Castilletti C; National Institute for Infectious Diseases "L. Spallanzani" IRCCS, 00149 Rome, Italy.
  • Vaia F; National Institute for Infectious Diseases "L. Spallanzani" IRCCS, 00149 Rome, Italy.
  • Liuzzi G; National Institute for Infectious Diseases "L. Spallanzani" IRCCS, 00149 Rome, Italy.
Viruses ; 14(7)2022 07 21.
Article in English | MEDLINE | ID: covidwho-1957452
ABSTRACT
With SARS-CoV-2 infection, pregnant women may be at a high risk of severe disease and adverse perinatal outcomes. A COVID-19 vaccination campaign represents the key strategy to combat the pandemic; however, public acceptance of maternal immunization has to be improved, which may be achieved by highlighting the promising mechanism of passive immunity as a strategy for protecting newborns against SARS-CoV-2 infection. We tested the anti-SARS-CoV-2 antibody response following COVID-19 full-dose vaccination in the serum and amniotic fluid of two pregnant women who presented between April and June 2021, at the Center for the Treatment and Prevention of Infections in Pregnancy of the National Institute for Infectious Diseases "L. Spallanzani", for antenatal consultancy. Anti-SARS-CoV-2 IgG was found in residual samples of amniotic fluid collected from both women at the 18th week of gestation (63 and 131 days after the second dose's administration). Titers in amniotic fluid mirrored the levels detected in serum and were inversely linked to the time from vaccination. Our results suggest that antibodies elicited by COVID-19 vaccination can cross the placenta and reach the fetus; therefore, they may offer passive immunity at birth. It is critical to fully understand the kinetics of the maternal response to vaccination, the efficiency of IgG transfer, and the persistence of antibodies in infants to optimize maternal immunization regimens.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pregnancy Complications, Infectious / COVID-19 Type of study: Case report / Observational study / Prognostic study / Randomized controlled trials Topics: Vaccines Limits: Female / Humans / Infant / Infant, Newborn / Pregnancy Language: English Year: 2022 Document Type: Article Affiliation country: V14071592

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Pregnancy Complications, Infectious / COVID-19 Type of study: Case report / Observational study / Prognostic study / Randomized controlled trials Topics: Vaccines Limits: Female / Humans / Infant / Infant, Newborn / Pregnancy Language: English Year: 2022 Document Type: Article Affiliation country: V14071592